TALPHERA, INC. (TLPH)
Pharmaceutical Preparations · market cap $61M · as of 2026-07-16
Research and calibrated estimates, not financial advice — verify before acting.
- 2026-12-31Regulatoryimp 5/10
- 2027-01-01 (est.)NDA Filingimp 6/10
| Asset | Phase | Indication |
|---|---|---|
| sufentanil sublingual | Phase 3 | Moderate-to-severe Acute Pain |
| Oral sufentanil | Phase 2 | Major Upper or Lower Abdominal Surgery |
| Sufentanil NanoTab PCA System | Phase 3 | Pain, Postoperative |
| Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03) | Phase 2 | Sedation |
| Zalviso™ | Phase 3 | Moderate-to-severe Acute Pain |
| Sufentanil | Phase 3 | Post-Operative Pain |
| Sufentanil NanoTab | Phase 2 | Post Operative Pain |
| morphine IV PCA | Phase 3 | Post-Operative Pain |
Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
- SEC filings — EDGAR filings for TLPH (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.
